| Nov 5 |
OnKure to Present at the Stifel 2024 Healthcare Conference
|
| Nov 1 |
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
|
| Oct 24 |
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond
|
| Oct 23 |
OnKure files to sell 2.94M shares of Class A Common Stock for holders
|
| Oct 10 |
OnKure started at outperform by Oppenheimer, OKI-219 potential cited
|
| Oct 7 |
OnKure and Reneo Pharmaceuticals complete merger
|
| Oct 4 |
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
|
| Oct 3 |
Reneo stockholders approve merger with OnKure
|
| Oct 3 |
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
|
| Aug 13 |
Reneo Pharmaceuticals GAAP EPS of -$0.16
|
